Neurologic Complications of Endocrine Disorders
ABSTRACT
OBJECTIVE
This article reviews the neurologic manifestations of endocrine disorders with respect to pathophysiology, clinical presentation, diagnosis, and treatment.
LATEST DEVELOPMENTS
Studies have further elucidated the mechanisms by which endocrine disorders affect neurologic function, from peripheral nervous system manifestations of diabetes to central nervous system complications of pituitary apoplexy. Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat obesity and diabetes are associated with an increased risk of developing diabetic lumbosacral radiculoplexus neuropathy and common peroneal neuropathy.
ESSENTIAL POINTS
Neurologic complications of endocrine disorders are diverse and may arise before systemic manifestations. Therefore, neurologists should consider endocrine diseases in the differential diagnosis of syndromes such as altered mental status, coma, peripheral neuropathy, and myopathy, and be familiar with the appropriate evaluation for these disorders.
Related Continuum Audio
Available to subscribers.
EPISODE DETAILS
Related Continuum Aloud
Available to subscribers.
EPISODE DETAILS
Get full access to this article
Purchase, subscribe, or recommend this article to your librarian.
REFERENCES
1.
Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003;112(11):1603-1618.
2.
Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023;329(16):1386-1398.
3.
Harrington MH, Casella SJ. Pituitary tumors in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):63-67.
4.
Wang MTM, Meyer JA, Danesh-Meyer HV. Neuro-ophthalmic evaluation and management of pituitary disease. Eye Lond Engl. 2024;38(12):2279-2288.
5.
Levy MJ, Matharu MS, Meeran K, Powell M, Goadsby PJ. The clinical characteristics of headache in patients with pituitary tumours. Brain J Neurol. 2005;128(Pt 8):1921-1930.
6.
Ajlan A, Achrol AS, Albakr A, et al. Cavernous sinus involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endonasal resection. J Neurol Surg Part B Skull Base. 2017;78(3):273-282.
7.
Arnardóttir S, Järås J, Burman P, et al. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur J Endocrinol. 2022;186(3):329-339.
8.
Vouzouneraki K, Esposito D, Mukka S, et al. Carpal tunnel syndrome in acromegaly: a nationwide study. Eur J Endocrinol. 2021;184(2):209-216.
9.
Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268-332.
10.
Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804-826.
11.
McNab TL, Khandwala HM. Acromegaly as an endocrine form of myopathy: case report and review of literature. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2005;11(1):18-22.
12.
Panos GD, Hafezi F, Gatzioufas Z. Visual outcomes after pituitary surgery. Swiss Med Wkly. 2013;143:w13802.
13.
Agam MS, Wedemeyer MA, Wrobel B, Weiss MH, Carmichael JD, Zada G. Complications associated with microscopic and endoscopic transsphenoidal pituitary surgery: experience of 1153 consecutive cases treated at a single tertiary care pituitary center. J Neurosurg. 2019;130(5):1576-1583.
14.
Wijdicks EFM. Neurologic Manifestations of Renal and Electrolyte Disorders. Contin Minneap Minn. 32(3, Neurology of Systemic Diseases):57-74.
15.
Donegan D, Erickson D. Revisiting pituitary apoplexy. J Endocr Soc. 2022;6(9):bvac113.
16.
Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary apoplexy. Endocr Rev. 2015;36(6):622-645.
17.
Singh TD, Valizadeh N, Meyer FB, Atkinson JLD, Erickson D, Rabinstein AA. Management and outcomes of pituitary apoplexy. J Neurosurg. 2015;122(6):1450-1457.
18.
Boellis A, di Napoli A, Romano A, Bozzao A. Pituitary apoplexy: an update on clinical and imaging features. Insights Imaging. 2014;5(6):753-762.
19.
Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005;65(5):668-675.
20.
Ishii M. Neurologic complications of nondiabetic endocrine disorders. Contin Minneap Minn. 2014;20(3 Neurology of Systemic Disease):560-579.
21.
Ranganathan S, Lee SH, Checkver A, et al. Magnetic resonance imaging finding of empty sella in obesity related idiopathic intracranial hypertension is associated with enlarged sella turcica. Neuroradiology. 2013;55(8):955-961.
22.
Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri: population studies in Iowa and Louisiana. Arch Neurol. 1988;45(8):875-877.
23.
Saindane AM, Lim PP, Aiken A, Chen Z, Hudgins PA. Factors determining the clinical significance of an “empty” sella turcica. AJR Am J Roentgenol. 2013;200(5):1125-1131.
24.
Chen BS, Meyer BI, Saindane AM, Bruce BB, Newman NJ, Biousse V. Prevalence of incidentally detected signs of intracranial hypertension on magnetic resonance imaging and their association with papilledema. JAMA Neurol. 2021;78(6):718-725.
25.
Fischbeck KH, Layzer RB. Paroxysmal choreoathetosis associated with thyrotosicosis. Ann Neurol. 1979;6(5):453-454.
26.
Schneider SA, Tschaidse L, Reisch N. Thyroid disorders and movement disorders: a systematic review. Mov Disord Clin Pract. 2023;10(3):360-368.
27.
Thomas FB, Mazzaferri EL, Skillman TG. Apathetic thyrotoxicosis: a distinctive clinical and laboratory entity. Ann Intern Med. 1970;72(5):679-685.
28.
Jabbari B, Huott AD. Seizures in thyrotoxicosis. Epilepsia. 1980;21(1):91-96.
29.
Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients: clinical features and treatment outcomes. Med J Aust. 1996;164(4):200-203.
30.
Wieland DR, Wieland JR, Wang H, et al. Thyroid disorders and dementia risk: a nationwide population-based case-control study. Neurology. 2022;99(7):e679-e687.
31.
Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010;41(5):961-966.
32.
Squizzato A, Gerdes VEA, Brandjes DPM, Büller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke. 2005;36(10):2302-2310.
33.
Duyff R. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. Published online June 1, 2000.
34.
Havard CW, Campbell ED, Ross HB, Spence AW. Electromyographic and histological findings in the muscles of patients with thyrotoxicosis. Q J Med. 1963;32:145-163.
35.
Ramsay ID. Electromyography in thyrotoxicosis. Q J Med. 1965;34(135):255-267.
36.
Verhagen WI, Schimsheimer RJ. Neurologic disease and thyrotoxic storm: a clinical and electrophysiological study. Electromyogr Clin Neurophysiol. 1986;26(1):27-32.
37.
Chang CC, Cheng CJ, Sung CC, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol. 2013;169(5):529-536.
38.
Falhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine. 2013;43(2):274-284.
39.
Kubiszewska J, Szyluk B, Szczudlik P, et al. Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. Brain Behav. 2016;6(10):e00537.
40.
Wijdicks E. F. M. The Comatose Patient. 2nd ed. Oxford University Press; 2014.
41.
Leigh H, Kramer SI. The psychiatric manifestations of endocrine disease. Adv Intern Med. 1984;29:413-445.
42.
Burkholder DB, Klaas JP, Kumar N, Boes CJ. The origin of Woltman’s sign of myxoedema. J Clin Neurosci Off J Neurosurg Soc Australas. 2013;20(9):1204-1206.
43.
Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007;22(4):224-231.
44.
Horak HA, Pourmand R. Endocrine myopathies. Neurol Clin. 2000;18(1):203-213.
45.
Sindoni A, Rodolico C, Pappalardo MA, Portaro S, Benvenga S. Hypothyroid myopathy: a peculiar clinical presentation of thyroid failure. review of the literature. Rev Endocr Metab Disord. 2016;17(4):499-519.
46.
Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164(9):1021-1025.
47.
Gallagher G, Rabquer A, Kerber K, Calabek B, Callaghan B. Value of thyroid and rheumatologic studies in the evaluation of peripheral neuropathy. Neurol Clin Pract. 2013;3(2):90-98.
48.
England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):185-192.
49.
Brain L, Jellinek EH, Ball K. Hashimoto’s disease and encephalopathy. Lancet Lond Engl. 1966;2(7462):512-514.
50.
Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30-39.
51.
Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233.
52.
Bertorini TE, Perez A. Neurologic complications of disorders of the adrenal glands. Handb Clin Neurol. 2014;120:749-771.
53.
Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. Eur J Endocrinol. 2024;190(5):G25-G51.
54.
Ruff RL, Weissmann J. Endocrine myopathies. Neurol Clin. 1988;6(3):575-592.
55.
Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847-875.
56.
Piasecka M, Papakokkinou E, Valassi E, et al. Psychiatric and neurocognitive consequences of endogenous hypercortisolism. J Intern Med. 2020;288(2):168-182.
57.
Dekkers AJ, Amaya JM, van der Meulen M, Biermasz NR, Meijer OC, Pereira AM. Long-term effects of glucocorticoid excess on the brain. J Neuroendocrinol. 2022;34(8):e13142.
58.
Nieman LK. Diagnosis of Cushing’s syndrome in the modern era. Endocrinol Metab Clin North Am. 2018;47(2):259-273.
59.
Martinez-Thompson JM. Electrodiagnostic assessment of myopathy. Neurol Clin. 2021;39(4):1035-1049.
60.
Sun J, Wang Y, Zhang X, Zhu S, He H. Prevalence of peripheral neuropathy in patients with diabetes: a systematic review and meta-analysis. Prim Care Diabetes. 2020;14(5):435-444.
61.
Abbott CA, Malik RA, van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220-2224.
62.
Callaghan BC, Gao L, Li Y, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018;5(4):397-405.
63.
Callaghan BC, Xia R, Banerjee M, et al. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care. 2016;39(5):801-807.
64.
Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646-655.
65.
Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications. J Diabetes Investig. 2018;9(6):1239-1254.
66.
Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2016;40(1):136-154.
67.
Hannaford A, Paling E, Silsby M, Vincenten S, van Alfen N, Simon NG. Electrodiagnostic studies and new diagnostic modalities for evaluation of peripheral nerve disorders. Muscle Nerve. 2024;69(6):653-669.
68.
Perkins B, Bril V. Electrophysiologic testing in diabetic neuropathy. Handb Clin Neurol. 2014;126:235-248.
69.
Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;2012(6):CD007543.
70.
Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. Neurology. 2022;98(1):31-43.
71.
Ellenberg M. Diabetic truncal mononeuropathy: a new clinical syndrome. Diabetes Care. 1978;1(1):10-13.
72.
Bell DSH. Diabetic mononeuropathies and diabetic amyotrophy. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2022;13(10):1715-1722.
73.
Streib EW, Sun SF, Paustian FF, Gallagher TF, Shipp JC, Ecklund RE. Diabetic thoracic radiculopathy: electrodiagnostic study. Muscle Nerve. 1986;9(6):548-553.
74.
Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999;53(9):2113-2121.
75.
Pinto MV, Ng PS, Howe BM, et al. Lumbosacral radiculoplexus neuropathy: neurologic outcomes and survival in a population-based study. Neurology. 2021;96(16):e2098-e2108.
76.
Ng PS, Dyck PJ, Laughlin RS, Thapa P, Pinto MV, Dyck PJB. Lumbosacral radiculoplexus neuropathy: incidence and the association with diabetes mellitus. Neurology. 2019;92(11):e1188-e1194.
77.
Pinto MV, Ng PS, Laughlin RS, et al. Risk factors for lumbosacral radiculoplexus neuropathy. Muscle Nerve. 2022;65(5):593-598.
78.
Triplett JD, Pinto MV, Young NP, et al. GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation. Neurology. 2025;105(3):e213916.
79.
Tracy JA, Engelstad JK, Dyck PJB. Microvasculitis in diabetic lumbosacral radiculoplexus neuropathy. J Clin Neuromuscul Dis. 2009;11(1):44-48.
80.
Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995;52(11):1053-1061.
81.
Dyck PJ, Norell JE, Dyck PJ. Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Can J Neurol Sci J Can Sci Neurol. 2001;28(3):224-227.
82.
Dyck P, O’Brien P, Bosch E. The multi-center double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 2006;66(5):A191.
83.
Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain J Neurol. 2015;138(Pt 1):43-52.
84.
Gibbons CH. Treatment induced neuropathy of diabetes. Auton Neurosci Basic Clin. 2020;226:102668.
85.
van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. 2020;8(4):325-336.
86.
Umpierrez G, Korytkowski M. Diabetic emergencies: ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222-232.
87.
Chua CB, Sun CK, Hsu CW, Tai YC, Liang CY, Tsai IT. “Diabetic striatopathy”: clinical presentations, controversy, pathogenesis, treatments, and outcomes. Sci Rep. 2020;10(1):1594.
88.
Abe Y, Yamamoto T, Soeda T, et al. Diabetic striatal disease: clinical presentation, neuroimaging, and pathology. Intern Med Tokyo Jpn. 2009;48(13):1135-1141.
89.
Singh A. Diabetic striatopathy. Mayo Clin Proc. 2013;88(8):e89.
90.
Bessemer RA, Tay KY, Budhram A. Teaching neuroimage: hyperglycemia-induced occipital lobe seizures. Neurology. 2023;101(8):e852-e853.
91.
Wang CP, Hsieh PF, Chen CCC, et al. Hyperglycemia with occipital seizures: images and visual evoked potentials. Epilepsia. 2005;46(7):1140-1144.
92.
Bathla G, Policeni B, Agarwal A. Neuroimaging in patients with abnormal blood glucose levels. AJNR Am J Neuroradiol. 2014;35(5):833-840.
93.
Chen CCC, Chai JW, Wu CH, Chen WS, Hung HC, Lee SK. Neuroimaging in seizure patients associated with nonketotic hyperglycemia. Neuroradiol J. 2011;24(2):215-220.
Letters to the Editor
Information and Authors
Information
Published In
Continuum®
Volume 32 • Number 1 • February 2026
Neurology of Systemic Disease
Pages: 105-130
Guest Editor: Aaron L. Berkowitz, MD, PhD, FAAN
PubMed: 41631909
Copyright
© 2026 American Academy of Neurology.
Publication History
Received: October 24, 2025
Published in issue: February 2026
Authors
Metrics and Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
